Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCL3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCL3 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CXCL3 Products |
| Gene Delivery | CXCL3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CXCL3 Products |
| Benchmark Ab | Anti-CXCL3 Recombinant Antibody Recombinant positive control for assay validation. |
View CXCL3 Products |
| Validator | CXCL3 siRNA Set For target knockdown and specificity verification. |
View CXCL3 Products |
| Related Target A | CXCR2 Primary GPCR receptor for CXCL3; critical for functional chemotaxis assays. |
View CXCR2 Products |
| Related Target B | CXCL1 Subfamily homolog sharing CXCR2 receptor; essential for selectivity screening. |
View CXCL1 Products |
| Related Target C | CXCL2 Subfamily homolog; required for off-target and cross-reactivity profiling. |
View CXCL2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Selectivity (CXCL1/2/3/8) | Homolog panel proteins strictly verified by mass spectrometry and sequence analysis. |
| GPCR Functional Assays (CXCR2 Activation) | Lentivirus premade particles available for stable CXCR2 cell line construction. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included. |
| Off-Target False Positives | Sequence-specific validated siRNA sets included for target knockdown verification. |
Live CXCL3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the CXCL3/GRO Gamma axis is rapidly gaining traction, particularly in the context of the tumor microenvironment (TME) and neutrophil-mediated inflammatory pathways. As a key chemoattractant acting through the CXCR2 receptor, CXCL3 plays a pivotal role in recruiting myeloid-derived suppressor cells (MDSCs) and tumor-associated neutrophils (TANs), which drive immune evasion and resistance to immune checkpoint inhibitors (ICIs).
The race for CXCL3 therapeutics is intensifying, with major players shifting focus from traditional systemic anti-inflammatory mAbs to targeted oncology therapeutics and combination regimens. As first-generation CXCR2 antagonists reach the clinic, the next wave of R&D is targeting the specific blockade of CXCL3 and its sister chemokines (CXCL1, CXCL2) to selectively inhibit immunosuppressive cell recruitment without causing systemic neutropenia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAb) | Academic Institutes, Biotech Startups | Solid Tumors, Metastatic Melanoma, COPD | High-affinity ligand binding assays (Need high-purity recombinant CXCL3) |
| Small Molecule Inhibitors | AstraZeneca, Dompé Farmaceutici | Inflammatory Diseases, Cancer Immunotherapy | Receptor-ligand competition assays (Need CXCR2 stable cell lines & CXCL3 ligand) |
| Combination Therapies (with PD-1/PD-L1) | Major Oncology Pharma | Immune-cold Tumors (Colorectal, Pancreatic) | In vitro cell migration and chemotaxis validation (Need functional CXCL3 & target knockdowns) |